BioCentury
ARTICLE | Clinical News

RP6530: Phase I started

December 23, 2013 8:00 AM UTC

Rhizen began an open-label, dose-escalation, Italian Phase I trial to evaluate twice-daily oral RP6530 in up to 42 patients. ...



Access The Full Article